Herein is reported a series of national and international projects for which the Center has been coordinator or partner. The efficacy of the research activity and in particular the technology transfer is testified by the high number of publications and the several patents that the members of the Center have filled throughout the time, and that can be retrieved in the personnel table. BIOPHARMANET-TEC commits to protect IP rights connected to the research activity carried out within the Center. (IPR protection). Concerning the IP rights generated as contractor for third parties, the Center refers to the “Regulation for patents and IP rights” of the Parma University. Within each project, the Center signs with the customer a “non-disclosure agreement” where the two parts are committed to keep data and information generated in the development of the project confidential, otherwise the contract is broken, and penalty clauses are enforced. Aim of the agreement is to protect every industrial secret and safeguard commercial information. The Center has established a code of conduct. Each member of the Center, both tenured and temporary, is required to sign a confidentiality agreement. Before signing, members are made aware of the deontological meaning of this conduct, which is thought to establish a mutual sense of trust with the client and safeguard future professional relationships. ONGOING PROJECTS AI4CHEMOBRAIN “AI4ChemoBrain – A machine learning/artificial intelligence model for personalized medicine: development of a predictive demonstrator for chemotherapy-induced cognitive impairment based on omic and phenotypic subject-derived data” The AI4CHEMOBRAIN project aims to develop a predictive demonstrator for the onset of cognitive complications during and after chemotherapy, for clinical use, based on a machine learning/artificial intelligence model trained and validated with preclinical data sets. Funding entity: Emilia-Romagna Region, PR-FESR 2021 – 2027 BIOPHARMANET-TEC (UniPr, Partner) GLYMED “Repurposing glycosaminoglycans in new drugs for the treatment of degenerative osteoarticular diseases” The GLYMED project involves research activities aimed at developing new drugs that utilize a glycosaminoglycan such as pentosan polysulfate (PPS) for the treatment of degenerative osteoarticular diseases like osteoarthritis. Funding entity: Emilia-Romagna Region, PR-FESR 2021 – 2027 Research entities: BIOPHARMANET-TEC (UniPr, Principal Investigator). TRAINEXTB The BIOPHARMANET-TEC center participated in the call for expressions of interest to support projects to be presented at the European level through expert consultancy. The selected project is ‘TRAINEXTB,’ coordinated by Prof. Marco Pieroni, which aims to participate in the MRSA-DN2024 call. The project’s main technological goal is the identification, through the combination of cutting-edge chemical and biological technologies, of new antimycobacterial molecules that could become the subject of patents and further development. At the same time, highly specialized professionals in the pharmaceutical field will be trained through an extensive training program. In fact, the MSCA funding scheme covers expenses by the European Community to fund 3-year doctoral scholarships at European universities and research centers, including BIOPHARMANET-TEC. Funding entity: Emilia-Romagna Region, 2023-2025 THREE-YEAR PRODUCTIVE ACTIVITIES PROGRAM UNIRECONDITION “The project aims to develop a biotechnological product – SANOO – for the perfusion of organs intended for transplants. Thousands of patients in Italy, in fact, wait for an organ transplant every year. This need can be partially met through ex vivo reconditioning of organs that are typically not considered of sufficient quality for transplantation, thus expanding the pool of potential donors. An essential component of this approach involves molecules capable of maintaining organ oxygenation. The SANOO product aims to meet this medical and market need. SANOO has already been developed as a validated laboratory technology (TRL 4).” Funding entity: Emilia-Romagna Region, PR-FESR 2021 – 2027 Research entities: BIOPHARMANET-TEC (UniPr, Principal Investigator).
